When new treatments, trial opportunities, and better care pathways exist, the real question becomes: can patients reach the right specialist fast enough for it to matter? Sandra Abrevaya, CEO of Synapticure, joins the podcast with host Michelle Snyder to unpack how she and her husband turned a personal ALS diagnosis journey into a mission to change access to neurology care at scale. Abrevaya shares about founding I Am ALS and helping drive major federal progress in ALS research funding and legislation. The conversation also digs into the gap between scientific breakthroughs and real-world care delivery, the “care and cures” strategy, and why Synapticure treats clinical data as a core asset from the start.
LINKS:
HealthEdge
McKesson Ventures
Synapticure
